Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study

Research output: Contribution to journalJournal articleResearchpeer-review

  • Torben Stamm Mikkelsen
  • Aissata Diop Mamoudou
  • Ruta Tuckuviene
  • Peder Skov Wehner
  • Henrik Schroeder

View graph of relations

Alkalized hydration is used as supportive care to prevent renal toxicity during infusions with high-dose methotrexate (HDMTX). In children with acute lymphoblastic leukemia (ALL), the hydration is commonly initiated 4 hours before start of the methotrexate (MTX) infusion. To test if longer duration of prehydration would prevent MTX-induced renal toxicity, we preformed a randomized cross-over study comparing 12-4 hours of hydration before the infusion of HDMTX.
JournalPediatric Blood & Cancer
Issue number2
Pages (from-to)297-301
Publication statusPublished - Feb 2014

    Research areas

  • Adolescent, Adult, Antimetabolites, Antineoplastic, Child, Child, Preschool, Combined Modality Therapy, Cross-Over Studies, Female, Fluid Therapy, Follow-Up Studies, Humans, Infant, Infusions, Intravenous, Kidney Diseases, Lymphoma, Non-Hodgkin, Male, Methotrexate, Neoplasm Staging, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Prognosis, Prospective Studies, Time Factors, Tissue Distribution, Young Adult